Literature DB >> 33563221

Predictive value of elevated alanine aminotransferase for in-hospital mortality in patients with acute myocardial infarction.

Jian Li1, Zhuo Zhao2, Hui Jiang3, Minjie Jiang1, Ge Yu1, Xu Li4.   

Abstract

BACKGROUND AND AIMS: Liver enzymes, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), are markers of hepatic dysfunction and fatty liver disease. Although ALT and AST have been suggested as risk factors for cardiovascular disease, their role as predictors of mortality after acute myocardial infarction (AMI) has not been established. The objective of this study was to investigate the predictive value of ALT and AST for mortality in patients with AMI.
METHODS: We analyzed records of 712 patients with AMI and no known liver disease treated at the Department of Cardiovascular Center in the First Hospital of Jilin University. The primary outcome was all-cause in-hospital mortality. Relationships between primary outcome and various risk factors, including serum transaminase levels, were assessed using multivariate logistic regression analysis.
RESULTS: Age (P < 0.001), hypertension (P = 0.034), prior myocardial infarction (P < 0.001), AST (P < 0.001), ALT (P < 0.001), creatinine (P = 0.007), blood urea nitrogen (P = 0.006), and troponin I (P < 0.001) differed significantly between ST-segment elevation myocardial infarction (STEMI) and non-STEMI. The following factors were associated with an increased risk of in-hospital all-cause mortality in patients with AMI: ALT ≥ 2ULN (adjusted odds ratio [AOR] 2.240 [95% confidence interval (CI), 1.331-3.771]; P = 0.002); age ≥ 65 year (AOR 4.320 [95% CI 2.687-6.947]; P < 0.001); increased fasting plasma glucose (FPG) (AOR 2.319 [95% CI 1.564-3.438]; P < 0.001); elevated D-dimer (AOR 2.117 [95% CI 1.407-3.184]; P < 0.001); elevated fibrinogen (AOR 1.601 [95% CI 1.077-2.380]; P = 0.20); and reduced estimated glomerular filtration rate (eGFR) (AOR 2.279 [95% CI 1.519-3.419]; P < 0.001).
CONCLUSIONS: Our findings demonstrated that elevated ALT was independently associated with increased in-hospital all-cause mortality in patients with AMI. Other risk factors were increased age, FPG, D-dimer, and fibrinogen and decreased eGFR.

Entities:  

Keywords:  Acute myocardial infarction; Alanine transaminase; Fasting plasma glucose; Liver enzymes; Mortality; eGFR

Year:  2021        PMID: 33563221     DOI: 10.1186/s12872-021-01903-z

Source DB:  PubMed          Journal:  BMC Cardiovasc Disord        ISSN: 1471-2261            Impact factor:   2.298


  1 in total

1.  Effect of acute kidney injury on long-term mortality in patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock who underwent primary percutaneous coronary intervention in a high-volume tertiary center.

Authors:  Mert İlker Hayıroğlu; Emrah Bozbeyoglu; Özlem Yıldırımtürk; Ahmet İlker Tekkeşin; Seçkin Pehlivanoğlu
Journal:  Turk Kardiyol Dern Ars       Date:  2020-01
  1 in total
  4 in total

1.  Diagnostic efficacy of serum ST2 in patients with ASC.

Authors:  Yaping Ren; Min Hou; Yunxia Ren; Lei Zhang
Journal:  J Clin Lab Anal       Date:  2022-05-25       Impact factor: 3.124

2.  High Aspartate Aminotransferase/Alanine Aminotransferase Ratio May Be Associated with All-Cause Mortality in the Elderly: A Retrospective Cohort Study Using Artificial Intelligence and Conventional Analysis.

Authors:  Kei Nakajima; Mariko Yuno; Kazumi Tanaka; Teiji Nakamura
Journal:  Healthcare (Basel)       Date:  2022-04-02

Review 3.  From Classic to Modern Prognostic Biomarkers in Patients with Acute Myocardial Infarction.

Authors:  Cristian Stătescu; Larisa Anghel; Bogdan-Sorin Tudurachi; Andreea Leonte; Laura-Cătălina Benchea; Radu-Andy Sascău
Journal:  Int J Mol Sci       Date:  2022-08-15       Impact factor: 6.208

4.  Outcomes of hyperlactatemia on admission in critically ill patients with acute myocardial infarction: A retrospective study from MIMIC-IV.

Authors:  Ting Lu; Liao Tan; Kai Xu; Jia Liu; Chong Liu; Guogang Zhang; Ruizheng Shi; Zheng Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-23       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.